Radiotherapy is an important treatment modality in head and neck cancer, including oral squamous cell carcinoma (OSCC), effectively killing cancer cells by causing DNA damage through the generation of reactive oxygen species (ROS) ([@bib37]). However, cancer cells with an antioxidant ability can escape the damaging effects of radiation by scavenging ROS, thus leading to radioresistance ([@bib6]). This radioresistance continues to be a major clinical obstacle to the cure of OSCC.

Exposure to clinically relevant doses of radiation is known to not only induce DNA damage but also activate a large network of inflammatory signalling pathways ([@bib5]). In addition, radiation-induced inflammation has a pivotal role in inducible radioresistance for cancer cells ([@bib23]). Therefore, if we can interrupt the inflammatory networks by targeting the inflammatory key molecule, we may offer a novel therapeutic approach to improve the clinical outcome of radiotherapy by enhancing radiosensitivity. However, the details regarding the molecular mechanism of inflammation-induced radioresistance remain unclear in OSCC.

Interleukin-6 is a multifunctional cytokine that was originally determined to regulate immune and inflammatory responses and inhibits apoptosis in toxic environments during inflammation ([@bib11]). Interleukin-6 is also known to act as a crucial player in developing chronic inflammation, resulting in immune escape and acceleration of tumour progression ([@bib23]). The biological effects of IL-6 are well known to be mediated through the activation of signal transducer and activator of transcription 3 (STAT3), and STAT3 has been shown to have a critical role in the interaction between tumour-associated macrophages (TAMs) and tumour cells within the tumour microenvironment, thereby leading to resistance to chemotherapy and radiotherapy ([@bib33]; [@bib20]; [@bib14]). Indeed, we previously demonstrated that higher numbers of TAMs contributed to resistance to chemoradiotherapy in OSCC ([@bib21]). We also recently showed that circulating high concentrations of IL-6 were positively correlated with the systemic inflammatory response, such as an elevated neutrophil-to-lymphocyte ratio, which predicts a poor response to chemoradiotherapy in OSCC patients ([@bib26]). However, the biological roles of IL-6 on radiosensitivity in OSCC have not yet been fully elucidated.

The Nrf2-Keap1 system is currently recognised as one of the main cellular defence mechanisms against oxidative stress ([@bib29]). Under basal conditions, Nrf2 (nuclear factor erythroid 2-related factor 2) is sequestered by the repressor Kelch-like ECH-associated protein1 (Keap1) in the cytoplasm and constitutively degraded through the ubiquitin-proteasome pathway ([@bib29]). Under oxidative stress, Nrf2 escapes Keap1-mediated repression and translocates into the nucleus to induce the transcription of numerous cytoprotective genes ([@bib29]). The autophagy-adaptor protein p62 interacts with the Nrf2-binding site on Keap1 and phosphorylation of p62 markedly increases p62\'s binding affinity for Keap1, thus inducing the expression of cytoprotective Nrf2 targets ([@bib13]; [@bib12]). However, recent studies have revealed that the Nrf2-mediated antioxidant pathway is implicated in the radioresistance of cancer cells ([@bib37]).

Accumulating evidence indicates that IL-6 and the Nrf2-mediated antioxidant pathway both contribute to treatment resistance in various cancers ([@bib37]; [@bib9]; [@bib14]; [@bib26]). However, the interplay between IL-6 and Nrf2 signalling pathway remains largely unknown. In the present study, we therefore investigated the biological roles of IL-6 on radiosensitivity and the relationship between IL-6 and Nrf2 activation in OSCC and found that increased levels of IL-6 confer radioresistance by suppressing oxidative stress via the Nrf2-antioxidant pathway in OSCC.

Materials and methods
=====================

Reagents
--------

Recombinant human IL-6 was purchased from Pepro Tech (Rocky Hill, NJ, USA), and the humanised anti-IL-6 receptor (IL-6R) monoclonal antibody (IgG1 class) tocilizumab was purchased from Chugai Pharmaceutical Co., Ltd (Tokyo, Japan).

Clinical samples from the patients
----------------------------------

For the histopathological analysis, primary oral cancer tissue samples were obtained from 22 patients with advanced OSCC treated at Kumamoto University Hospital between October 2003 and October 2009. All of the patients were preoperatively treated with a total dose of 30 Gy of concurrent chemoradiotherapy followed by curative surgery as a phase II study ([@bib25]; [@bib32]). Radiotherapy was administered at a daily dose of 2 Gy five times a week for 15 days. The study followed the guidelines of the Ethics Committee of Kumamoto University. The nature and aims of the study were explained to all patients, and all gave their informed consent for the research.

Immunohistochemistry
--------------------

Formalin-fixed specimens were embedded in paraffin, cut into 4 *μ*m sections, and mounted on MAS-GP-coated slides (Matunami Glass Ind., LTD, Osaka, Japan). The sections were heated with an autoclave in 10 *μ*mol l^−1^ citrate buffer (pH 6.0 or 9.0) for 15 min at 121 °C for antigen retrieval after deparaffinisation and rehydration. The sections were incubated with 3% H~2~O~2~ in absolute methanol for 30 min to block endogenous peroxidase activity. Then, nonspecific background staining was blocked using Protein Block Serum Free Reagent (Dako, Glostrup, Denmark) for 15 min, followed by overnight incubation at 4 °C with anti-human IL-6 (1 : 50; Abcam, Cambridge, UK), anti-human phospho-STAT3 (Thy705) (1 : 100; Cell Signaling Technology, Danvers, MA, USA), anti-human IL-6 receptor *α* (IL-6R*α*) (1 : 100; Santa Cruz Biotechnology, Inc., Dallas, TX, USA), anti-human CD163 (1 : 100; Leica Biosystems, Heidelberger, Germany), anti-human Cytokeratin AE1/AE3 (1 : 200; Dako), anti-human phospho-Nrf2 (1 : 100; Abcam), anti-human Mn-SOD (1 : 100; Merck Millipore, Billerica, MA, USA) antibodies diluted in a phosphate-buffered saline (PBS) solution containing 1% bovine serum albumin (BSA). This was followed by sequential 60 min incubations with the secondary antibodies (EnVision+ System-HRP Labelled Polymer; Dako), and visualisation with the Liquid DAB+ Substrate Chromogen System (Dako). All of the slides were lightly counterstained with haematoxylin for 30 s before dehydration and mounting.

Cell lines and cell culture
---------------------------

The human OSCC cell lines derived from the primary tumour, SAS and HSC-2 were obtained from the Japanese Collection of Research Bioresources bank of the National Institutes of Biomedical Innovation, Health and Nutrition (Osaka, Japan), and cultured with DMEM supplemented with 10% FBS and maintained under humidified 5% CO~2~ incubation at 37 °C.

Irradiation
-----------

A dose of 6 and 10 Gy irradiation was performed in a 150-KVp X-ray generator (Model MBR-1520R, Hitachi, Tokyo, Japan) with a total filtration of 0.5 mm aluminium plus 0.1 mm copper filter. The dose rate measured by a thimble ionisation chamber (IC 17A, Far West Technology, Goleta, CA, USA) was 1.01 Gy min^−1^.

Cell proliferation assay
------------------------

To assess the normal proliferation, viable cells under IL-6 treatment (0, 50, and 200 pg ml^−1^) with or without irradiation (0, 2, 6, and 10 Gy) were quantified every 24 h using the Cell Counting Kit-8 (Dojindo, Kumamoto, Japan).

Enzyme-linked immunosorbent assay for the detection of secreted IL-6
--------------------------------------------------------------------

The cells (2 × 10^5^) were seeded in a 60 mm tissue culture dish (Asahi Techno Glass Co., LTD, Shizuoka, Japan) and incubated in DMEM with 1% FBS for 24 h. The cells were then irradiated with 6 and 10 Gy of X-rays. At 12, 24, 36, 48, and 60 h after irradiation, the conditional culture media were collected, and the concentration of IL-6 was measured using a Human IL-6 Quantikine enzyme-linked immunosorbent assay (ELISA) Kit (R&D Systems, Minneapolis, MN, USA) in accordance with the manufacturer\'s instructions.

RNA isolation and real-time quantitative PCR
--------------------------------------------

Total RNA was isolated from the treated cells using mirVana miRNA Isolation Kit (Life Technologies, Palo Alto, CA, USA). Total RNA was then reverse-transcribed to cDNA using a ReverTra qPCR RT Kit (Toyobo, Osaka, Japan). Each PCR reaction was run using a Thunderbird SYBR qPCR Mix (Toyobo) on a Light Cycler 1.5 (Roche, Indianapolis, IN, USA). The comparative Ct (ΔΔCt) method was used to determine the fold changes in the expression using glyceraldehyde-3-phospate dehydrogenase (GAPDH). Each sample was run in triplicate. The following primers were used: Keap1 (forward, 5′-GGGTCCCCTACAGCCAAG-3′ reverse, 5′-TGGGGTTCCAGAAGATAAGC-3′); GAPDH (forward, 5′-CAACAGCCTCAAGATCATCAGC-3′ reverse, 5′-TTCTAGACGGCAGGTCAGGTC-3′). The cycling conditions were as follows: initial denaturation at 98 °C for 5 min followed by 45 cycles at 98 °C for 15 s, 58 °C for 30 s, and 72 °C for 60 s. These experiments were performed in triplicate.

The modified high-density survival assay
----------------------------------------

The modified high-density survival (HDS) assay was performed according to the method of [@bib16]). Exponentially growing cells (5 × 10^5^) were seeded in a 60 mm tissue culture dish (Asahi Techno Glass Co., LTD) and incubated in DMEM with 1% FBS for 48 h. The cells treated with various concentrations of IL-6 (0, 50, and 200 pg ml^−1^) were then exposed to 6 Gy of X-rays. After 72 h incubation, 10% of the cells in each flask were seeded in a new 60 mm culture dish with various concentrations of IL-6 and incubated for a further 72 h. Finally, the total number of cells in each culture dish was counted via the Trypan blue dye exclusion test, and the survival of the cells was plotted. Similarly, 20 ng ml^−1^ tocilizumab was added to the cells in the modified HDS assay.

Clonogenic assay
----------------

After a single exposure to 6 Gy of X-rays, the cells (1 × 10^3^) were seeded in a 60 mm culture dish coated with gelatin (Asahi Techno Glass Co., LTD) under treatment with control agents or 100 pg ml^−1^ IL-6 and incubated in DMEM with 1% FBS for 10 days. After 10 days, the cells were fixed with 99.5% methanol and stained with Giemsa solution (Wako, Osaka, Japan).

Immunofluorescent staining and evaluation
-----------------------------------------

The cells (2 × 10^4^) were seeded onto glass slides (Merck Millipore) and incubated in DMEM with 1% FBS for 24 h. Then, IL-6 at 200 pg ml^−1^ and tocilizumab at 20 ng ml^−1^ were added to the cells, and the cells were exposed to 10 Gy of X-rays. After 24 (*γ*-H2AX) or 48 h (Nrf2, Keap1, and phospho-p62) incubation, the cells were fixed in 4% paraformaldehyde in a PBS solution for 30 min. The cells were then washed with PBS-T for 5 min and blocked with PBS-T with 5% BSA for 5 min on ice. After blocking, the cells were incubated for 2 h at room temperature, with the primary antibodies against phosphorylated histone H2AX (*γ*-H2AX) (1 : 00; Merck Millipore), Nrf2 (1 : 50; Abcam), Keap1 (1 : 400; Cell Signaling Technology), and phospho-p62 (1 : 5000; Medical & Biological Laboratories Co., LTD, Woburn, MA, USA) in PBS-T with 1% BSA. Subsequently, the glass slides were washed with PBS-T three times (5 min each), and the cells were incubated for 1.5 h at room temperature with the secondary antibodies (Alexa Fluor 488 and 594 donkey anti-rabbit and/or anti-mouse IgG; Life Technologies) in PBS-T with 1% BSA. After being washed with PBS, the cells were counterstained and mounted with Vectashield (Vector Laboratories, Inc., Burlingame, CA, USA) and examined with a fluorescent microscope (Model BZ-X700; KEYENCE, Osaka, Japan). About evaluating the *γ*-H2AX foci, if the cell had ⩾10 *γ*-H2AX foci per nucleus, the cell was considered to be positive for *γ*-H2AX ([@bib30]).

Western blot analysis
---------------------

The whole-cell and nuclear protein (Minute Cytoplasmic and Nuclear Extraction Kits; Invent Biotechnologies, Inc., Eden Prairie, MN, USA) were separated using 7.5 or 12.5% SDS--PAGE, transferred onto nitrocellulose membranes, and probed with antibodies against phospho-Nrf2 (S40; 1 : 15 000; Abcam), phospho-STAT3 (Thy705; 1 : 500; Cell Signaling Technology), Keap1 (1 : 1000; Cell Signaling Technology), phospho-p62 (1 : 1000; Medical & Biological Laboratories Co., LTD), Lamin B1 (1 : 10 000; Abcam), and *β*-actin (1 : 10 000; Sigma, St Louis, MO, USA). After overnight incubation at 4 °C, the membranes were washed and incubated with appropriate horseradish peroxidase-conjugated secondary antibodies and visualised using the ECL prime detection kit (GE Healthcare, Buckinghamshire, UK).

Immunoprecipitation
-------------------

The cells proteins were extracted in RIPA buffer (25 mM Tris·HCl (pH 7.6), 150 m[M]{.smallcaps} NaCl, 1% NP-40, 1% sodium deoxycholate, and 0.1% SDS) containing a protease inhibitor cocktail (Roche Diagnostics). Then, the total proteins were cleaned and incubated with 5 *μ*g of specific antibody against Keap1 to form immunocomplexes, which were precipitated with protein A-Sepharose (GE Healthcare). Finally, the presence of immunocomplexes was detected by a western blotting analysis.

Cellular ROS/superoxide detection assay
---------------------------------------

The cells (2 × 10^4^) were seeded onto 24-well plates (Asahi Techno Glass Co., LTD) and incubated in DMEM with 1% FBS for 24 h. Next, IL-6 at 0 and 200 pg ml^−1^ and tocilizumab at 20 ng ml^−1^ were added, and the cells were exposed to 10 Gy of X-rays. After 48 h incubation, the appearance of ROS/superoxide in the cells was detected using Cellular ROS/Superoxide Detection Assay Kit (Abcam). The observations to obtain these findings were done under a fluorescent microscope.

Statistical analysis
--------------------

The differences in the mean values between the two groups were statistically analysed using Student\'s *t*-test, whereas the differences in the mean values among multiple groups were analysed using a one-way ANOVA with the Bonferroni/Dunn test. All *P*-values were based on two-tailed statistical analyses, and *P*-values \<0.05 were considered to be statistically significant (\**P*\<0.05 and \*\**P*\<0.01).

Results
=======

IL-6 levels in the tumour microenvironment of irradiated OSCC tissues
---------------------------------------------------------------------

To examine the clinical significance of IL-6 in the tumour microenvironment, we assessed the expression levels of IL-6 by immunohistochemistry using surgical tissue specimens, which contained surviving OSCC cells after preoperative 30 Gy of chemoradiotherapy. Representative photographs illustrating the expression patterns of various molecules are shown in [Figure 1](#fig1){ref-type="fig"}. As shown in [Figure 1B](#fig1){ref-type="fig"}, increased levels of IL-6 were observed in the tumour cells and stromal cells. Among the stromal cells, CD163-positive M2 macrophages and TAMs around tumour cells overexpressed IL-6 ([Figure 1B and F](#fig1){ref-type="fig"}). In addition, high expression levels of IL-6 signalling molecules, such as IL-6R*α* and phospho-STAT3, were also observed in AE1/AE3-positive tumour cells ([Figure 1E](#fig1){ref-type="fig"}) and the surrounding stromal cells ([Figure 1C and D](#fig1){ref-type="fig"}). These results suggest that increased levels of IL-6 and IL-6 signalling may promote the development of radioresistance in both autocrine and paracrine manners in the tumour microenvironment of OSCC tissues.

IL-6 effect on the radiation-induced cell death of OSCC cells
-------------------------------------------------------------

To clarify the biological impacts of IL-6 in the tumour microenvironment, we performed *in vitro* experiments. First, we examined the effects of IL-6 in irradiated OSCC cells using a modified HDS assay. Irradiated OSCC cells under IL-6 treatment showed significantly lower radiosensitivity than the control cells ([Figure 2A and B](#fig2){ref-type="fig"}). Regarding the radioprotective effect of IL-6, the same result was confirmed by a clonogenic assay ([Figure 2C and D](#fig2){ref-type="fig"}). We then examined the cellular growth activities of the OSCC cells with or without IL-6 treatment by a cell proliferation assay. Interleukin-6 had no significant effect on the cell proliferation in any OSCC cells, regardless of irradiation ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}), indicating that the radioresistance elicited by IL-6 is not due to an increased cell proliferation. We also examined the amount of extracellularly released IL-6 in the conditioned media at 48 h after X-ray irradiation without IL-6 treatment using an ELISA kit ([Supplementary Figure 2A and B](#sup1){ref-type="supplementary-material"}). Despite the lack of marked differences in cell proliferation between X-ray-irradiated and non-irradiated cells at 48 h after irradiation, the release of IL-6 in the irradiated OSCC cells was significantly higher than that observed in the non-irradiated cells. Furthermore, a significant level of IL-6R*α* expression was confirmed in these cell lines at both the gene and protein levels (data not shown). These results suggest that extracellularly released IL-6 from OSCC cells after irradiation may contribute to radioresistance in an autocrine manner.

Effect of IL-6 signalling blockade on OSCC cell radiosensitisation
------------------------------------------------------------------

Next, we confirmed whether or not the blockade of IL-6 signalling affects radiosensitivity in irradiated OSCC cells. We examined the radiosensitivity of irradiated OSCC cells under treatment with either or both IL-6 or the humanised anti-human IL-6R antibody tocilizumab using a modified HDS assay. The photographs under phase-contrast microscopy show the surviving cells after radiation under each treatment condition ([Figure 3A and C](#fig3){ref-type="fig"}). The addition of tocilizumab to IL-6 or to the control agent significantly decreased the surviving fraction compared with IL-6 or control alone ([Figure 3B and D](#fig3){ref-type="fig"}). These results suggest that the blockade of IL-6 signalling sensitises OSCC cells to radiation.

Contribution of IL-6 signalling to decreased DNA damage in the irradiated OSCC cells
------------------------------------------------------------------------------------

Next, we investigated whether or not IL-6 affects the number of double-stranded DNA breaks in irradiated OSCC cells. *γ*-H2AX was used to quantitate the double-stranded DNA breaks attributed to X-ray irradiation. We identified the cells with ⩾10 *γ*-H2AX foci by counting at 1, 3, 6, 24, and 48 h after 10 Gy irradiation ([@bib30]; [@bib15]). The frequency of *γ*-H2AX-positive SAS cells under IL-6 (20.0%±3.1%) was lower than that under control conditions (68.5%±7.3%) at 24 h after irradiation ([Figure 4A and B](#fig4){ref-type="fig"}). However, the frequency of *γ*-H2AX-positive cells under tocilizumab alone or IL-6 plus tocilizumab treatment was higher than that under control conditions ([Figure 4C](#fig4){ref-type="fig"}) or IL-6 treatment alone ([Figure 4D](#fig4){ref-type="fig"}). In addition, IL-6 treatment significantly reduced the number of double-stranded DNA breaks from the early stage to 48 h after irradiation ([Figure 4E](#fig4){ref-type="fig"}).

Effect of IL-6 on the activation of the Keap1/Nrf2 system in the irradiated OSCC cells
--------------------------------------------------------------------------------------

As recent studies have revealed that Nrf2 is involved in cancer radioresistance, we next examined the effect of IL-6 on the activation of Nrf2 in OSCC cells. As shown in [Figure 5A](#fig5){ref-type="fig"}, a subtle increase in the Nrf2 expression in the cytoplasm and nucleus was observed in the cells after 10 Gy irradiation by immunofluorescence. In addition, IL-6 treatment significantly increased the expression level of Nrf2 in the cytoplasm and nucleus of the irradiated cells ([Figure 5A](#fig5){ref-type="fig"}). Western blot analyses showed that IL-6 activated not only the downstream molecule STAT3 but also Nrf2 in the irradiated cells ([Figure 5B](#fig5){ref-type="fig"}). In addition, IL-6 treatment of irradiated OSCC cells did not change the mRNA or protein levels of Keap1, an inhibitor of Nrf2, but increased the protein level of phospho-p62 ([Figure 5C and D](#fig5){ref-type="fig"}). These data suggest that IL-6 promotes Nrf2 activation by upregulating the interaction between Keap1 and p62 in the irradiated cells. Associated with this phenomenon, immunofluorescence of the irradiated cells revealed a higher number of colocalisations of Keap1 and p62 under IL-6 treatment ([Figure 5E](#fig5){ref-type="fig"}). Reflecting these results, the dissociation between Keap1 and Nrf2 was observed in the IL-6-treated irradiated cells ([Figure 5F](#fig5){ref-type="fig"}).

Effect of IL-6 on the oxidative stress regulation in the irradiated OSCC cells
------------------------------------------------------------------------------

Next, we investigated whether or not IL-6 modulates oxidative stress via Nrf2-antioxidant pathway in the irradiated OSCC cells. We examined the expression of Mn-SOD, an Nrf2-dependent ROS scavenger ([@bib24]), in irradiated cells under IL-6 treatment. Western blot analyses revealed that IL-6 enhances the expression of Mn-SOD via Nrf2 activation, while tocilizmab inhibits the expression ([Figure 6A](#fig6){ref-type="fig"}). Reflecting these results, IL-6 decreased the amount of ROS/superoxide, and tocilizumab inhibited these effects ([Figure 6B](#fig6){ref-type="fig"}). We also confirmed the involvement of the IL-6/Nrf2-antioxidant pathway in some specimens from patients with OSCC that showed resistant to 30 Gy of chemoradiotherapy. The representative results of immunohistochemical staining for IL-6, phospho-Nrf2, and Mn-SOD are shown in [Figure 6C](#fig6){ref-type="fig"}. As expected, the expression levels of IL-6, phospho-Nrf2, and Mn-SOD were increased in almost all specimens. We summarised the experimental evidence of IL-6-mediated radioresistance model in the tumour microenvironment of irradiated OSCC tissue based on our data in [Figure 6D](#fig6){ref-type="fig"}.

Discussion
==========

In the present study, we observed a number of meaningful findings. First, an increased level of IL-6 conferred radioresistance to OSCC cells by protecting them from oxidative damage. Second, IL-6 activated the Nrf2-antioxidant pathway. To our knowledge, no other reports have identified the molecular mechanisms underlying IL-6-mediated radioresistance in OSCC. In addition, given the growing evidence that upregulated IL-6 in the tumour microenvironment promotes malignant phenotypes, leading to treatment resistance ([@bib10]; [@bib9]; [@bib14]), it is noteworthy that we uncovered the interplay between IL-6 and the Nrf2-antioxidant pathway, which will help develop novel IL-6-targeting therapies.

There have been some reports showing an association between IL-6 and the radioresistance of cancer cells ([@bib7]; [@bib2]; [@bib1]; [@bib31]). Two reports on prostate cancer ([@bib31]) and liver cancer ([@bib3]) cited findings consistent with our own, showing that IL-6 protects cancer cells from radiation-induced oxidative DNA damage. In addition, one report in lung cancer further showed that IL-6 signalling promotes DNA repair in CD133-positive cancer stem cell-like cells ([@bib4]). As we did not evaluate the effects of IL-6 on DNA repair, whether or not IL-6 promotes DNA repair in OSCC remains unknown. However, our present findings suggest that IL-6 could be a potential target for overcoming radioresistance in many cancers.

Radiation is known to significantly contribute to the generation of ROS in various cells, and it can induce DNA damage and oxidative stress responses ([@bib17]). In contrast, Nrf2 is a key transcriptional regulator of genes encoding numerous cytoprotective enzymes in response to oxidative stress, such as excessive ROS ([@bib37]). Among such Nrf2-dependent cytoprotective enzymes, Mn-SOD is crucial for radioresistance, due to its ability to scavenge ROS and superoxide ([@bib8]; [@bib35]). Indeed, as shown in [Figure 6A and B](#fig6){ref-type="fig"} in our study, Nrf2-dependent Mn-SOD expression levels have been linked to the ability to scavenge ROS and superoxide. These results suggest that radiosensitivity in OSCC cells can be regulated by the Nrf2-antioxidant pathway, a notion supported by evidence showing that the suppression of the Nrf2-antioxidant pathway sensitises tumour cells to radiation in lung cancer ([@bib18]; [@bib19]; [@bib36]), breast cancer ([@bib22]), and prostate cancer ([@bib34]).

Radiation therapy promotes inflammatory responses in the tumour tissues, and the upregulation of cytokines such as IL-6 is not only a crucial mediator of inflammation but also confers a survival advantage to tumour cells ([@bib5]). Regarding the interplay between IL-6 and the Nrf2 signalling pathway, to our knowledge, no one has demonstrated that IL-6 activates the Nrf2-antioxidant pathway after radiation against OSCC cells. To test our hypothesis, in addition to evaluating the Nrf2 activation via western blot ([Figure 5B and D](#fig5){ref-type="fig"}) and immunoprecipitation ([Figure 5F](#fig5){ref-type="fig"}) analyses, we confirmed the subcellular localisation of Nrf2 and Nrf2 activation-related molecules (Keap1 and p62) in the cells by immunofluorescence ([Figure 5A and E](#fig5){ref-type="fig"}). However, IL-6 is known to activate STAT3, which has a crucial role in radiation-induced inflammatory responses ([@bib23]). Therefore, the effects of radioresistance observed with increased levels of IL-6 may be brought about by not only Nrf2- but also STAT3-regulated function. However, we believe the novel finding that an IL-6-mediated Nrf2-antioxidant pathway is involved in radioresistance will prove of great import when targeting inflammatory networks to counter tumour radiosensitisation.

These present findings suggest that targeting the IL-6 signalling pathway combined with conventional radiotherapy could be a promising new approach for overcoming radioresistance in patients with OSCC. However, an inherent limitation of our study is that the novel findings obtained were based on mainly *in vitro* data, except for the immunohistochemical analysis using OSCC tissues. Therefore, further studies are needed to confirm the effects of combination therapy with targeting of IL-6 signalling and radiation using *in vivo* models. Regarding this point, given our previous finding that the therapeutic approach targeting IL-6R by tocilizumab is effective for OSCC treatment using an *in vivo* mouse model, we believe that tocilizumab might be useful for preclinically verifying our idea for tumour radiosensitisation ([@bib27], [@bib28]). Furthermore, tocilizumab has been approved for rheumatoid arthritis (RA) in more than 90 countries worldwide and is known to be very effective in the treatment of RA. Therefore, if preclinical findings using tocilizumab are promising in the cancer field, tocilizumab would be useful for clinical trial design from the viewpoint of drug repositioning.

In conclusion, we demonstrated for the first time that IL-6 controls resistance to radiation by suppressing oxidative stress via the Nrf2-antioxidant pathway in cancer. Our data indicate that blockade of IL-6 signalling in combination with conventional radiotherapy could augment the treatment response in patients with radioresistant OSCC, thereby improving the survival rate.
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![**Interleukin-6 levels are increased in the tumour microenvironment of irradiated OSCC tissues.**Representative microscopic images of H&E (**A**) and immunohistochemical staining of IL-6 (**B**), IL-6R*α* (**C**), phospho-STAT3 (**D**), AE1/AE3 (**E**), and CD163 (**F**). AE1/AE3 and CD163 were used as surrogate markers for tumour cells and TAMs, respectively. Scale bar, 100 *μ*m.](bjc2016327f1){#fig1}

![**Interleukin-6 suppresses the radiation-induced cell death of OSCC cells.**The survival fraction of SAS cells (**A**) and HSC-2 cells (**B**) after exposure to 6 Gy of X-rays was evaluated by a modified HDS assay under various concentrations of IL-6 (0, 50, and 200 pg ml^−1^). The results are shown as the means±s.d. of three independent experiments. \*\**P*\<0.01. (**C** and **D**) The photographs of the cell survival fraction as evaluated by a clonogenic assay. After exposure to 6 Gy of X-rays, the SAS and HSC-2 cells were seeded in 60 mm culture dishes under treatment with 0 or 100 pg ml^−1^ IL-6, and incubated. After 10 days\' culture, the cells were fixed and visualised.](bjc2016327f2){#fig2}

![**Blockade of IL-6 signalling sensitises OSCC cells to radiation.**(**A** and **B**) The modified HDS assay using SAS cells under control conditions, or 200 pg ml^−1^ IL-6, or 20 ng ml^−1^ tocilizumab, or 200 pg ml^−1^ IL-6 plus 20 ng ml^−1^ tocilizumab. The cells were exposed to 6 Gy of X-rays. The images of the survival fraction of SAS cells under phase-contrast microscopy (**A**) and the corresponding frequency graph (**B**). (**C** and **D**) The modified HDS assay using HSC-2 cells under control conditions, or 200 pg ml^−1^ IL-6, or 20 ng ml^−1^ tocilizumab, or 200 pg ml^−1^ IL-6 plus 20 ng ml^−1^ tocilizumab. The cells were exposed to 6 Gy of X-rays. The images of the survival fraction of HSC-2 cells under phase-contrast microscopy (**C**) and the corresponding frequency graph (**D**). The results are shown as the means±s.d. of three independent experiments. \**P*\<0.05 and \*\**P*\<0.01. Scale bar, 200 *μ*m.](bjc2016327f3){#fig3}

![**Interleukin-6 signalling helps reduce DNA damage in irradiated OSCC cells.**(**A**--**D**) Representative images of immunofluorescence of *γ*-H2AX foci under various conditions after exposure to 10 Gy of X-rays. The images of *γ*-H2AX foci in SAS cells are shown at 24 h under treatment with control (**A**), or 200 pg ml^−1^ IL-6 (**B**), or 20 ng ml^−1^ tocilizumab (**C**), or 200 pg ml^−1^ IL-6 plus 20 ng ml^−1^ tocilizumab (**D**) after irradiation. The arrows indicate the cells with ⩾10 *γ*-H2AX foci. (**E**) Frequencies of *γ*-H2AX-positive cells at each time after exposure to 10 Gy of X-rays under treatment with control or 200 pg ml^−1^ IL-6. The results are shown as the means±s.d. of three independent experiments. \**P*\<0.05 and \*\**P*\<0.01. Scale bar, 50 *μ*m.](bjc2016327f4){#fig4}

![**Interleukin-6 activates the Keap1/Nrf2 system in irradiated OSCC cells.**(**A**) The images of immunofluorescence of Nrf2 in SAS cells at 48 h after non-X-ray or 10 Gy of X-ray irradiation with or without 200 pg ml^−1^ IL-6. (**B**) The protein levels of Nrf2, phospho-Nrf2, and phospho-STAT3 in SAS cells at 48 h after non-X-ray or 10 Gy of X-ray irradiation with or without 200 pg ml^−1^ IL-6. The whole-cell and nuclear protein were prepared, and the expression of Nrf2, phospho-Nrf2, and phospho-STAT3 proteins was examined using a western blot analysis. (**C**) The expression of Keap1 mRNA in SAS cells at 48 h after non-X-ray or 10 Gy of X-ray irradiation with or without 200 pg ml^−1^ IL-6. (**D**) The protein levels of Keap1 and phospho-p62 in SAS cells. The western blot analysis was done using the same lysate as **B**. (**E**) The images of immunofluoresent double staining of Keap1 and phospho-p62 in SAS cells at 48 h after 10 Gy of X-ray irradiation with or without 200 pg ml^−1^ IL-6. The arrows indicate the activated phospho-p62. (**F**) The Nrf2/Keap1 complex formation detected by an immunoprecipitation analysis in SAS cells. After the same treatment as **B**, the cell lysates were immunoprecipitated using anti-Keap1 antibody. The immunoprecipitates were immunoblotted with anti-Nrf2 antibody.](bjc2016327f5){#fig5}

![**Interleukin-6 reduces oxidative stress via the Nrf2-antioxidant pathway in irradiated OSCC cells.**(**A**) At 48 h after non-irradiation or 10 Gy of X-ray irradiation with vehicle or 200 pg ml^−1^ IL-6, or 200 pg ml^−1^ IL-6 plus 20 ng ml^−1^ tocilizumab, whole-cell lysates in OSCC cells were prepared, and the expression of Mn-SOD and phospho-Nrf2 was examined by a western blot analysis. (**B**) At 48 h after 10 Gy of X-ray irradiation with vehicle or 200 pg ml^−1^ IL-6, or 200 pg ml^−1^ IL-6 plus 20 ng ml^−1^ tocilizumab, the superoxide/ROS were examined in SAS cells using a Cellular ROS/Superoxide Detection Assay Kit. Scale bar, 50 *μ*m. (**C**) Representative microscopic images of H&E and immunohistochemical staining of IL-6, phospho-Nrf2, and Mn-SOD. Scale bar, 25 *μ*m. (**D**) A schematic illustration of the IL-6-mediated radioresistance model. When OSCC tissue is exposed to X-ray irradiation, the increased level of IL-6 promotes the dissociation of Keap1 and Nrf2 via binding of Keap1 to phospho-p62, leading to Nrf2 activation. At the same time, the IL-6/STAT3 pathway is also activated. The activated Nrf2 and STAT3 then translocate to the nucleus and induce the expression of antioxidant enzymes such as Mn-SOD, and IL-6. The overexpressed IL-6 helps increase the resistance to radiation in both autocrine and paracrine manners in the tumour microenvironment.](bjc2016327f6){#fig6}
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